Results 51 to 60 of about 120,343 (298)

Time Toxicity in Wilms Tumor: Quantifying the Burden of Healthcare Interaction in the First Year After Diagnosis

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Wilms tumor (WT) treatment imposes a significant time burden on patients and their families. Time toxicity is a patient‐centered metric that quantifies the burden of healthcare interaction. We sought to define time toxicity in the first year after diagnosis of WT and hypothesized that it would increase as tumor stage and treatment ...
Caleb Q. Ashbrook, Veerain Gupta, Nicholas J. Clark, Vijay Rings, Lauren E. Corona, Douglass B. Clayton, Daniel J. Benedetti   +6 more
wiley   +1 more source

Effective Management of Carbapenem-Resistant Enterobacterales Bloodstream Infection with Organ Dissemination in Prolonged Severe Agranulocytosis Patients with Hematological Malignancy Through Combination Therapies Including Eravacycline

Infectious Diseases and Therapy
This study reports three patients with hematologic malignancy patients and Carbapenem-resistant Enterobacterales (CRE) bloodstream infections and organ dissemination during neutropenia.
Yuyuan Lv, Xin Zhang, Qingya Cui, Mengyun Li, Lian Bai, Yan Yu, XueKai Li, Xiaoqian Chen, Depei Wu, Xiaowen Tang   +9 more
doaj   +1 more source

Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph‐negative acute lymphoblastic leukemia relapsed post CD19 CART therapy

Clinical Case Reports, 2023
Key Clinical Message There are no reports of application of inotuzumab ozogamicin (InO) for the treatment of MRD in r/r B‐ALL. We firstly report the efficacy of InO for a patient experienced morphological relapse after HSCT and molecular relapse after ...
Si‐Man Huang, Chao‐Ling Wan, Han‐Yu Cao, Yan‐Yan Li, Chong‐Sheng Qian, Hai‐Xia Zhou, Ming‐Zhu Xu, Xiao‐Hui Hu, Lan Dai, Hai‐Ping Dai, Sheng‐Li Xue   +10 more
doaj   +1 more source

Heterogeneity in the Global Practice of Central Nervous System Staging in Pediatric Acute Lymphoblastic Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Central nervous system (CNS) involvement in childhood acute lymphoblastic leukemia (ALL) is assessed by cell counting and cytomorphology from cerebrospinal fluid (CSF) and is used for treatment stratification worldwide. The ratio of “CNS2” patients in clinical trials ranges from 3% to 40%, with unclear prognostic significance ...
Laura Almási, Bernadett Borbála Huszti, Gábor Barna, Marko Kavcic, Janez Jazbec, Lennart Lenk, Vera Münch, Sophia Polychronopoulou, Ágnes Márk, Maria Thastrup, Lüder H. Meyer, Kjeld Schmiegelow, Cornelia Eckert, Christina Halsey, Dániel J. Erdélyi   +14 more
wiley   +1 more source

Personalized Treatment for Hematologic Diseases in Europe: An EHA Position Paper

, 2020
Personalization of hematologic therapies is made possible by novel diagnostic methods and precisely targeted treatments. For Europe-wide routine implementation of personalized therapies for all patients with hematologic diseases some major technological,
Kapitein, Peter, Peter Kapitein, Gribben, John, Ulrich Jäger, John Gribben, Jäger, Ulrich   +5 more
core   +1 more source

Myeloid-Derived Suppressor Cells in Hematologic Diseases Promising Biomarkers and Treatment Targets [PDF]

, 2019
International audienceMyeloid-derived suppressor cells (MDSC) are a heterogeneous group of immature myeloid cells that exist at very low numbers in healthy subjects but can expand significantly in malignant, infectious, and chronic inflammatory diseases.
Sunčica Bjelica, Santibañez, Juan Francisco, Papadaki, Helen A., Kittang, Astrid Olsnes, Juan Francisco Santibañez, Nikoleta Bizymi, Marie Lipoldová, Bizymi, Nikoleta, Ersvaer, Elisabeth, Maria Velegraki, Bjelica, Sunčica, Slavko Mojsilovic, Charalampos Pontikoglou, Ersvær, Elisabeth, Pontikoglou, Charalampos, Lipoldová, Marie, Mikael Roussel, Velegraki, Maria, Papadaki, Helen A, Mojsilovic, Slavko, Roussel, Mikaël, Santibanez, Juan F., Elisabeth Ersvær, Helen A. Papadaki, Astrid Olsnes Kittang   +24 more
core   +1 more source

Emapalumab for Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CD19‐Directed CAR‐T in Two Patients With B‐ALL: Clinical and Biomarker Correlates

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Immune effector cell‐associated hemophagocytic lymphohistiocytosis‐like syndrome (IEC‐HS) is a life‐threatening hyperinflammatory toxicity distinct from cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen receptor T‐cell (CAR‐T) therapy. In a single‐institution retrospective cohort of pediatric and young adult patients
Thomas J. Galletta, Jeremy D. Rubinstein, Christopher E. Dandoy, Ruby Khoury, Angela Faulhaber, Christine L. Phillips, Christa Krupski   +6 more
wiley   +1 more source

The Role of Hematopoietic Cell Transplantation in Ataxia‐Telangiectasia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Ataxia‐telangiectasia (A‐T) is a DNA repair disorder characterized by neurodegeneration, immunodeficiency, and cancer predisposition. Hematopoietic cell transplantation (HCT) is an established therapy in related disorders such as Fanconi anemia (FA) and Nijmegen breakage syndrome (NBS), but its role in A‐T is unclear.
Laila Alkhouli, Seth Rotz, Masatoshi Takagi, Richa Sharma   +3 more
wiley   +1 more source

Hematologic Abnormalities and Diseases Associated with Moderate-to-Marked Basophilia in a Large Cohort of Dogs

, 2023
Basophilia is a rare hematologic finding in dogs. This research aimed to describe the hematologic and clinical characteristics of dogs with moderate-to-marked basophilia. CBC reports with blood smear examinations from dogs presented to the North Carolina
Elizabeth Held, Hiroyuki Mochizuki
core   +1 more source

Increased Risk of Sarcomas in Children With Congenital Anomalies: Findings From the Genetic Overlap Between Anomalies and Cancer in Kids (GOBACK) Registry Linkage Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Pediatric sarcomas are a heterogeneous group of tumors that contribute disproportionately to cancer mortality in children. Although congenital anomalies are among the strongest known risk factors for childhood cancer, the risk of specific sarcoma subtypes among affected individuals has not yet been thoroughly evaluated. Procedure We
Russ Wolters, Ji Yun Tark, Tiffany M. Chambers, Tania A. Desrosiers, Michael E. Scheurer, Charles Shumate, Wendy N. Nembhard, Mahsa M. Yazdy, Eirini Nestoridi, Amanda E. Janitz, Jean Paul Tanner, Russell S. Kirby, Jason L. Salemi, Yao Yu, Chad D. Huff, Sharon E. Plon, Philip J. Lupo, Jeremy M. Schraw   +17 more
wiley   +1 more source